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ABSTRACT. 
 
Rationale: RhoA and Rho kinase contribute to pulmonary vasoconstriction and vascular remodelling in 
pulmonary hypertension. RhoB, a protein homologous to RhoA and activated by hypoxia, regulates 
neoplastic growth and vasoconstriction but its role in the regulation of pulmonary vascular function is 
not known.  
 
Objective: To determine the role of RhoB in pulmonary endothelial and smooth muscle cell responses 
to hypoxia and in pulmonary vascular remodelling in chronic hypoxia-induced pulmonary hypertension.   
 
Methods and results. Hypoxia increased expression and activity of RhoB in human pulmonary artery 
endothelial and smooth muscle cells, co-incidental with activation of RhoA. Hypoxia or adenoviral 
overexpression of constitutively activated RhoB increased actomyosin contractility, induced endothelial 
permeability and promoted cell growth; dominant negative RhoB or manumycin, a farnesyltransferase 
inhibitor that targets the vascular function of RhoB, inhibited the effects of hypoxia. Coordinated 
activation of RhoA and RhoB maximized the hypoxia-induced stress fibre formation caused by 
RhoB/mDia-induced actin polymerisation and RhoA/Rho kinase-induced phosphorylation of myosin 
light chain on Ser19. Notably, RhoB was specifically required for hypoxia-induced HIF-1α stabilization 
and for hypoxia- and PDGF-induced cell proliferation and migration. RhoB deficiency in mice 
markedly attenuated development of chronic hypoxia-induced pulmonary hypertension, despite 
compensatory expression of RhoA in the lung.  
 
Conclusions: RhoB mediates adaptational changes to acute hypoxia in the vasculature, but its continual 
activation by chronic hypoxia can accentuate vascular remodelling to promote development of 
pulmonary hypertension. RhoB is a potential target for novel approaches (eg farnesyltransferase 
inhibitors) aimed at regulating pulmonary vascular tone and structure.  
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; U2OS-HRE-luc: human osteosarcoma cells 
stably expressing a luciferase reporter construct under the control of a hypoxia response element; MLC: 
myosin light chain; mDia: mammalian homolog of Drosophila diaphanous; VE-cadherin: vascular 
endothelial cadherin; PCNA: proliferating cell nuclear antigen; RVSP: right ventricular systolic 
pressure; CARhoB: constitutively activated (V14) RhoB; DNRhoB: dominant negative (N19)RhoB 
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Introduction.  
 
Chronic hypoxia-induced pulmonary hypertension is characterised by increased right ventricular 
afterload from increased pulmonary vascular resistance due to pulmonary vasoconstriction and 
pulmonary vascular remodelling
1
. Hypoxic pulmonary vasoconstriction (HPV) helps to maintain 
oxygen supply within physiological limits by diverting blood from poorly-ventilated to better ventilated 
areas of the lung
2
. Activation of RhoA/Rho kinase in pulmonary vasculature contributes to sustained 
HPV and pulmonary vascular remodelling in hypoxia-induced pulmonary hypertension and in other 
forms of pulmonary hypertension
3,4
. RhoA is a member of the Rho GTPases family of proteins, key 
regulators of actin-dependent processes such as cell adhesion, migration and proliferation
5
. In the 
vascular wall, activation of RhoA and Rho kinase increases SMC contractility, increases endothelial 
permeability, and inhibits NO generation by decreasing endothelial nitric oxide synthase (eNOS) 
expression and activity
6-8
. Inhibition of the RhoA/Rho kinase pathway contributes to the beneficial 
effects of sildenafil in PH but statins, another inhibitor of this pathway, have little effect on the course 
of human pulmonary hypertension
9-11
. 
 
Recent data implicate RhoB, a protein 85% homologous to RhoA and highly expressed in the lung
12
, in 
cell responses to oxidative stress. RhoB is activated by hypoxia
13,14
 and genotoxic stress
15
. Protein 
levels are turned over more rapidly than other Rho GTPases (120 minutes versus 24 hours, 
respectively)
16
. RhoA and RhoB interact with the same downstream targets in separate subcellular 
locations
17
. For instance, both proteins can activate Rho kinase and interact with a mammalian homolog 
of Drosophila diaphanous (mDia)
17,18
. Combined actions of Rho kinase and mDia induce actomyosin 
contraction in cells: mDia produces actin filaments by actin nucleation while Rho kinase increases 
phosphorylation of the myosin light chain (MLC) on Serine 19 promoting filament cross-linking and 
the formation of stress fibres
19
. RhoA and RhoB play opposing roles in malignant transformation
20
 but 
increasing evidence shows that RhoB can also enhance the effects of RhoA or compensate for the loss 
of RhoA function
21
.  
 
RhoB, like other Rho GTPases, requires prenylation for its biological activity, but is distinguished from 
homologous Rho proteins by being both farnesylated and geranylgeranylated, while other Rho isoforms 
are solely geranylgeranylated
18
. RhoB also lacks a PKA/PKG-specific phosphorylation site, important 
in the regulation of RhoA activity
18
. Geranylgeranylated and farnesylated RhoB are thought to have 
different functions in cells. Farnesylated RhoB localises to the cell membrane, promotes cell growth, 
mediates the effects of Ras on actin cytoskeleton and activates nuclear factor kappa B (NFB)22-24. In 
contrast, geranylgeranylated RhoB localises to endosomes
 
and induces cell apoptosis
22,25
.  
 
RhoB is a convergence point of several pathways implicated in the pathogenesis of pulmonary 
hypertension.  RhoB acts upstream of HIF-113 and NFB24, mediates the effects of transforming 
growth factor-β (TGF-β) and bone morphogenetic protein (BMP) on actin remodelling26,27, and 
regulates trafficking of platelet derived growth factor (PDGF) and epidermal growth factor (EGF) 
receptors as well as non receptor kinases src and Akt in cells, important in the regulation of cell 
survival and proliferation
22,28,29
. Genetic deletion of RhoB in mice does not adversely affect mouse 
development, though retarded retinal vascularisation has been noted
20
. Embryonic fibroblasts from 
RhoB null mice show increased sensitivity to TGF-stimulation20,29.  
 
This study addresses for the first time the role of RhoB in the regulation of pulmonary vascular 
responses to hypoxia in vitro and in vivo. We show that RhoB is required for hypoxia-induced 
cytoskeletal remodelling, increased endothelial permeability and associated growth responses in 
pulmonary vascular cells. Genetic deletion of RhoB attenuates development of chronic hypoxia-
induced pulmonary hypertension in mice, likely to result from inhibition of HIF signalling and reduced 
pulmonary vascular remodelling. 
 
Methods. 
An expanded Materials and Methods section is available in the Online Data Supplement. 
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Cell culture. Human pulmonary artery endothelial cells (HPAECs) were cultured in endothelial growth 
medium-2, while human pulmonary artery smooth muscle cells (HPASMCs) were cultured  in smooth 
muscle cell growth medium-2 under normoxic conditions (20% O2, 5% CO2) at 37°C. The cells were 
also exposed to hypoxia (2% O2, 5% CO2, 92% N2) for 1-48 hr.  
RT-PCR: Semiquantitative RT–PCR was performed with isoform-specific primers:  
RhoA                Forward   5’- CAGAAAAGTGGACCCCAGAA 
                         Reverse    5’- GCAGCTCTCGTAGCCATTTC 
RhoB                Forward   5’- GAGAACATCCCCGAGAAGTG  
                         Reverse    5’- CTTCCTTGGTCTTGGCAGAG  
GAPDH           Forward    5’- CCTGGCCAAGGTCATCCATGACA 
                         Reverse    5’ - GGGATGACCTTGCCCAC AGCCTT 
For mouse lung tissues, the primers and PCR conditions were used as in
17
.  
Rho GTPases protein expression and activity: RhoA and RhoB protein expression in cells and 
tissues was studied by immunofluorescence and Western blotting. Active RhoA and RhoB were 
measured with recombinant GST-RBD in GTP-loading assays
30
.  
Manipulation of RhoA/RhoB expression and activity in cultured cells: Over expression of AdGFP 
(adenoviral control), dominant negative RhoB (DNRhoB; Ad-6myc-N19RhoB-GFP), constitutively 
activated RhoB (CARhoB; Ad-HA-V14RhoB-GFP) and dominant negative RhoA (DNRhoA; Ad-Flag-
N19RhoA) was induced by adenoviral gene transfer
30
. Farnesyltransferase inhibitor, manumycin (Enzo; 
5 µmol/L; 2-48 hr incubation) was added to the cells at the start of hypoxic exposure or 1h prior the 
hypoxic exposure, as indicated. Rho kinase inhibitor, Y-27632 (5 µmol/L, Calbiochem) was added to 
the cells over expressing CARhoB 2 hr before cell fixation. mDia siRNA or non-targeting siRNA was 
introduced to cells by lipofectamine transfection and the experiments were carried out 72 hr post-
transfection. 
Endothelial cell permeability and morphology: The effects of hypoxia and RhoB over expression on 
transendothelial permeability were studied using HPAECs grown in Transwell-Clear chambers. 
Changes in cell morphology were observed using TRITC-phalloidin labelled F-actin and 
immunofluorescence staining of vascular endothelial (VE)-cadherin in cells grown on cover slips
30
, 
followed by confocal microscopy. 
Cell metabolic activity: An MTS colorimetric assay (Promega) was used to assess metabolic activity 
associated with cell proliferation and migration. PDGF-BB (20 µg/L) was added to cells in reduced 
serum (1% FCS) and growth factor-depleted medium and incubated for 48 hr. 
Cell migration was measured in an in vitro wound assay. HPASMC monolayer was scraped with the 
tip of a 100-l pipette and the number of cells that migrated out of the wound edge during o/n 
incubation was scored.  
HIF expression and activity: HIF activity was studied in a osteosarcoma cell line stably expressing a 
luciferase reporter construct under the control of a hypoxia response element (U2OS-HRE-luc) (kind 
gift of Dr M. Ashcroft, UCL). Changes in HIF-1α protein levels in cultured HPAECs was studied by 
Western blotting, while its localization was studied by immunofluorescence and confocal microscopy.  
Apoptosis: Apoptosis was assessed by measuring Tetramethylrhodamine, ethyl ester, perchlorate 
(TMRE) (Invitrogen) fluorescence in mitochondria of live cells using confocal microscopy and image 
analysis.  
Intracellular calcium levels in live cells were studied with Rhod3 imaging kit (Molecular Probes). 
Rhod3 fluorescence was measured in Glomax spectrophotometer (Promega) at excitation/emission 
550/580 nm. 
Normoxia and Chronic Hypoxia Studies in vivo: All studies were conducted in accordance with UK 
Home Office Animals (Scientific Procedures) Act 1986 and institutional guidelines. 15-week old 
C57BL male mice (200 g; Charles River, Margate, UK) and RhoB -/- male mice  (a kind gift of 
Professor Brian Morris) were either housed in normal air or placed in a normobaric hypoxic chamber 
(FIO2 10%) for 2 weeks (n= 4-8/group).
 
Development of PH was confirmed  as described previously
31
. 
Western blot analysis and immunostaining: RhoA, RhoB, MLC, MLC-P-Ser19, HIF-1α, VE-
cadherin, PCNA and β-actin protein expression was studied by western blotting and by 
immunofluorescence in cells or lung lysates, as appropriate.  
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Statistical analysis. All the experiments were performed in triplicate and data are presented as the 
mean ± standard error of mean. Comparisons between groups were carried out using two-tailed Student 
t-tests or one-way ANOVA as appropriate. Statistical significance was accepted for P≤0.05 and tests 
were performed using GraphPad Prism version 4.0 or Microsoft Office Excel 2007. 
 
Results 
 
Hypoxia increases RhoB expression and activity.    
Exposure of HPAECs and HPASMCs to hypoxia induced a 2-fold increase in RhoB gene expression, 
maximal between 0.5-2 hr of hypoxia (Figure 1A, B). RhoB protein levels and activity also increased 
significantly, reaching maximum between 2-4 hr (Figure 1A, B).  While RhoA gene and protein 
expression
30,32 
remained relatively unchanged, we observed a 2-fold increase in RhoA activity in both 
HPAECs and HPASMCs, coincident with RhoB activation (Figure 1C, D).  
 
RhoB mediates hypoxia-induced cytoskeletal remodelling in pulmonary vascular cells.  
Hypoxia (1-24 hr) induced stress fibre formation in HPAECs and HPASMCs, and dispersion of 
intercellular adherens junction protein, VE-cadherin, in HPAECs (Figure 2A, B and Supplementary 
Figure 1). To examine the role of RhoB in modulating the pulmonary cell phenotype, cells were 
infected with adenoviruses to induce over expression of AdGFP (adenoviral control), constitutively 
activated RhoB (CARhoB; V14RhoB-GFP) or dominant negative RhoB (DNRhoB; N19RhoB-GFP), 
or were treated with manumycin (5 mol/L, 2 hr incubation), a farnesyltransferase inhibitor that ablates 
RhoB function.  AdGFP (adenoviral control) did not affect cell phenotype in normoxia or in hypoxia 
(Supplementary Figure 1). CARhoB increased stress fibre levels in cells and induced dispersion of 
intercellular adherens junctions in HPAECS in normoxia, mimicking the effects of hypoxia (Figure 2A, 
B and Supplementary Figure 1); conversely, DNRhoB and manumycin inhibited the effects of hypoxia 
(Figure 2A, B).  
 
Changes in the localization of VE-cadherin in hypoxia were accompanied by a significant, 2-fold 
increase in endothelial permeability (Figure 2C). CARhoB increased endothelial permability in 
normoxia (3-fold increase, comparison with normoxic control) and in hypoxia (2.4-fold increase, 
comparison with hypoxic control), while DNRhoB and manumycin preserved endothelial junctional 
integrity in hypoxic conditions (Figure 2C).  
 
RhoA is highly homologous to RhoB and could compensate for changes in RhoB activity. CARhoB 
had no effect while DNRhoB induced a small (1.2-fold) increase in RhoA activity in cells 
(Supplementary Figure 2). To investigate the contribution of RhoA to hypoxia-induced morphological 
remodelling we overexpressed the dominant negative RhoA (DNRhoA; N19RhoA) alone or in 
combination with DNRhoB in cells. DNRhoA attenuated hypoxia-induced stress fibre formation 
(Supplementary Figure 3) and prevented a hypoxia-induced increase in endothelial permeability (Figure 
2C), consistent with previous reports
30
.  The combination of RhoA and RhoB inhibition was similar to 
that of manumycin (Figure 2C). Manumycin inhibits RhoB activity but not RhoA, consistent with the 
fact that RhoB but not RhoA exists as a farnesylated isoform in vivo (Supplementary Figure 4). We 
conclude that RhoA and RhoB are both important in the regulation of hypoxia-induced responses and 
that RhoB inhibition is not masked by a compensatory increase in RhoA activity. 
 
RhoA and RhoB cooperate in stress fibre formation in pulmonary vascular cells. 
Phosphorylation of Serine 19 in myosin light chains is required for actomyosin contraction and is 
promoted by hypoxia (Figure 3A, B). MLC phosphorylation was maximal between 2-4 hr of hypoxic 
exposure (Figure 3A, B) and co-incided with RhoA/RhoB activation and stress fibre formation in cells. 
CARhoB enhanced MLC phosphorylation, partially mimicking the effects of hypoxia (1.8-fold increase 
in normoxia, P≤0.01, compared with untreated normoxic control), (Figure 3C, D). Inhibition of RhoB 
and RhoA, separately, reduced MLC phosphorylation (1.5-fold decrease and 2.5 decrease, respectively, 
compared with hypoxic control) (Figure 3C, D). Combined inhibition of RhoA and RhoB had a greater 
inhibitory effect (5.7-fold reduction compared to hypoxic control, P≤0.001), suggesting that both RhoA 
and RhoB contribute to hypoxia-induced MLC phosphorylation of Ser19 (Figure 3C, D). Of note, 
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DNRhoB and manumycin completely abolished MLC-pSer19 localization to stress fibres 
(Supplementary Figure 5). 
 
In contrast to RhoA, the effects of RhoB appear to be largely independent of Rho kinase. The putative 
Rho kinase inhibitor, Y-27632, had very little effect on CARhoB-induced cell morphology (Figure 4). 
Similarly, dominant-negative RhoA (DNRhoA) did not affect the CARhoB-induced cell phenotype in 
HPAECs and HPASMCs (Supplementary Figure 6). In contrast, manumycin or knockdown of formin 
mDia completely abolished CARhoB-induced stress fibre formation in cells (Figure 4).  
 
MLC phosphorylation of Serine 19 in cells is regulated by changes in intracellular calcium levels as 
well as by Rho kinase. We therefore examined the effects of RhoB on intracellular calcium levels in 
cells using a fluorescent calcium indicator, Rhod3. Hypoxia increased intracellular calcium levels in 
HPAECs and in HPASMCs (1.2-fold and 1.5-fold increase respectively), consistent with other reports
33
, 
but RhoB activation or inhibition did not have an effect (Supplementary Figure 7A,B).  
 
RhoB  mediates proliferative and migratory responses of pulmonary vascular cells to hypoxia. 
Hypoxia induced a 1.3-fold increase in growth response in HPAECs and a greater, 1.7-fold increase in 
HPASMCs (P≤0.05 and P≤0.001 respectively, compared with normoxic controls; Figure 5A, B). 
Manipulation of RhoB activity did not affect HPAECs in normoxia, but RhoB was required for the 
growth response in hypoxia (Figure 5A). In contrast, HPASMC growth responses relied on RhoB 
activity in both normoxic and in hypoxic conditions (Figure 5B). DNRhoA expressed alone had no 
significant impact on cell growth, and did not augment the effect of DNRhoB, suggesting that RhoB 
rather than RhoA is involved in hypoxia-induced growth of pulmonary vascular cells.  
 
RhoB is important in recycling and membrane targeting of the PDGF receptor
28,34
. PDGF-BB is an 
important stimulator of HPASMC growth and migration in hypoxic conditions, contributing to 
pulmonary vascular remodelling in pulmonary hypertension
34,35
. Both DNRhoB and manumycin 
inhibited PDGF-stimulated HPASMC growth, comparable to that caused by the PDGFR tyrosine 
kinase inhibitor, imatinib (Figure 6A). Conversely, imatinib inhibited hypoxia-induced RhoB 
expression and activation in HPASMCs (Supplementary Figure 8) and the effect of overexpression of 
RhoB on HPASMC proliferation in normoxia and hypoxia (Figure 6C). Interestingly, both activated 
and inhibitory RhoB mutants abrogated cell migration, suggesting that finely choreographed dynamic 
changes in RhoB activity are required to support continuous remodelling of actin cytoskeleton and cell 
adhesion during cell movement (Figure 6B, D and Supplementary Figure 8).  
 
RhoB induces apoptosis in several types of cancer. However, in human pulmonary vascular cells, RhoB 
exerts a growth promoting rather than a pro-apoptotic effect, consistent with mouse studies 
documenting a function for RhoB in endothelial cell survival and angiogenesis
29
. Overexpression of 
RhoB mutant proteins for had no significant effect on cell apoptosis (Supplementary Figure 9). Short 
term (1-4 hr) incubation of cells with manumycin did not induce apoptosis (not shown) but 48 hr 
incubation had a pro-apoptotic effect (1.9-fold decrease in TMRE fluorescence, P≤0.05; comparison 
with untreated control) (Supplementary Figure 9).  
 
RhoB knockout attenuates development of chronic hypoxia-induced pulmonary hypertension. 
There were no significant differences in the right ventricular systolic pressure (RVSP) between the wild 
type and the RhoB-/- mice kept in normal air (Figure 7A). Following 2 weeks of hypoxia, the RVSP in 
wild type mice increased from 21.63±2.27 mmHg to 36.98±1.39 mmHg (1.7-fold increase, P≤0.001, 
compared with a normoxic group), while RhoB-/- mice showed a significantly attenuated response 
(increase from 20.54±1.87 to 26.09±0.92 mmHg; 1.3-fold increase, P≤0.001, compared with hypoxic 
wild type mice) (Figure 7A, B). 
 
Chronic hypoxia induced right ventricular hypertrophy in both wild type and RhoB -/- mice. This was 
significantly attenuated in RhoB -/- mice (P≤0.05, compared with hypoxic wild type mice; Figure 7C).  
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Pulmonary vascular muscularisation increased markedly in chronic hypoxia in both genotypes but to a 
significantly lesser degree in RhoB-/- mice (79% SD 9 vs 56% SD 15, respectively, P≤0.01; Figure 7 D, 
E).  
 
RhoB-/- genotype of each mouse was confirmed by PCR (Supplementary Figure 10). The effects of 
RhoB knockout were evident despite increases in RhoA expression. RhoB-/- mice showed a 
compensatory increase in RhoA expression in basal conditions (Supplementary Figure 10). Following 
exposure to chronic hypoxia, the lungs from wild type mice showed increased expression of both RhoA 
and RhoB, while the lungs of RhoB -/- mice showed increase in RhoA expression of similar magnitude 
to the wild type mice (Supplementary Figure 10).   
 
RhoB is required for hypoxic HIF-1 stabilization in vitro and in vivo.  
HIF-1α participates in hypoxia-induced pulmonary vascular remodelling33,36. To study the effect of 
RhoB on HIF activation, we used the human U2OS-HRE-luc cell line, which has been optimised and 
validated in studies of HIF inhibitors and hypoxia-induced HIF activation
37
. CARhoB significantly 
enhanced HIF-driven luciferase expression under hypoxic conditions (1.8-fold increase, P≤0.05, 
comparison with hypoxic controls), while DNRhoB and manumycin attenuated hypoxia-induced HIF 
activation (1.6- and 1.5-fold reduction in HIF activity respectively, comparison with hypoxic controls) 
(Figure 8A). DNRhoA alone or in combination with DNRhoB did not have an effect (Figure 8A).  
 
Stabilization of HIF-1α by RhoB in HPAECs was confirmed by Western blotting and immunostaining 
(Figure 8B, E, F). HIF-1α expression and nuclear localization was reduced in cells over expressing 
DNRhoB under hypoxic conditions, but not in cells over expressing DNRhoA (Figure 8B, E, F).  
 
Chronic hypoxia significantly increased lung HIF-1α levels in wild type mice (1.5-fold increase, P≤0.05, 
compared with normoxic wild type controls) (Figure 8C, F). Consistent with the hypothesized role of 
RhoB, the lungs from chronically hypoxic RhoB-deficient mice showed reduced accumulation of HIF-
1α (2.5-fold reduction, P≤0.05, comparison with hypoxic wild type controls) (Figure 8C, F). Changes in 
HIF accumulation were paralleled by changes in the expression levels of the proliferating cell nuclear 
antigen (PCNA). RhoB-/- mouse lungs showed significantly reduced PCNA expression (1.8-fold 
reduction, compared with hypoxic wild type controls, Figure 8D, F), consistent with decreased vascular 
remodelling. 
 
Discussion  
 
This study addresses for the first time the key integral role of RhoB in the regulation of the pulmonary 
vascular responses to hypoxia. We show that RhoB expression and activity are increased by hypoxia in 
cultured pulmonary vascular cells, coincident with the activation of RhoA. RhoB regulates cell 
proliferation, endothelial barrier function and cell contractility, and contributes to hypoxia-induced 
stabilisation of HIF-1α. Chronic hypoxia significantly increases RhoB expression in the lung and RhoB 
gene knockout in mice attenuates chronic hypoxia-induced PH, in spite of a compensatory increase in 
RhoA expression. Inhibition of RhoB farnesylation prevents the effects of hypoxia, an observation that 
might be exploited therapeutically using farnesyltransferase inhibitors.   
 
We show for the first time that manipulation of RhoB activity affects endothelial barrier function. 
Activation of RhoA has previously been implicated in hypoxia-induced increase in pulmonary 
endothelial permeability
30
. Activated RhoA induces stress fibre formation in endothelial cells
38
 as a 
result of increased actomyosin contractility. Increases in centripetal forces within cells counteract 
tethering forces created by intercellular adhesion molecules, compromising endothelial barrier 
function
39
. Interestingly, we observed that inhibition of either RhoA or RhoB prevented hypoxia-
induced increase in endothelial permeability in HPAECs, indicating that both GTPases were important, 
and consistent with their complementary effects on stress fibre formation.  
 
While there are reports of anti-neoplastic effects of RhoB in some types of cancer, it has growth-
promoting effects in numerous cell types
23,40,41
. Both RhoA and RhoB appeared to cooperate in 
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hypoxia-induced cytoskeletal remodelling, but RhoB played a unique role in the regulation of 
pulmonary vascular growth responses to hypoxia. The effects of RhoB on cell growth under hypoxic 
conditions are likely to be mediated by multiple effectors. RhoB is required for the actions of several 
growth factors induced by hypoxia and regulates endocytotic trafficking of pro-proliferative and anti-
apoptotic kinases Src and Akt
28,42
. There is also evidence that RhoB can activate pro-inflammatory 
transcription factor NFkB to much greater extent than RhoA
24
, a fact of potential importance in the 
regulation of inflammatory responses in the remodelled hypoxic lung. Here we show that the effect of 
RhoB on HPASMC proliferation is likely to be mediated by PDGF/PDGFR signaling. Imatinib, an 
inhibitor of PDGF receptor tyrosine kinase, abrogated the effects of over expressing RhoB on 
HPASMC growth in vitro. 
 
We also show that the effect of RhoB on hypoxia-induced pulmonary vascular responses in vitro and in 
vivo involve stabilisation of HIF-1, a transcription factor implicated in hypoxia-induced activation of 
PDGF receptor and pulmonary vascular remodelling
43,36
.RhoB prevents proteolytic degradation of 
HIF-1α by the Akt/glycogen synthase kinase-3β pathway in glioblastoma cells13. A relevant observation 
is that GTPase Rac1, which activates RhoB promoter, has been shown stabilise HIF-1α in hypoxic 
Hep3B cells
44
.  
 
These observations translate in vivo. RhoB -/- mice exposed to chronic hypoxia developed mild 
pulmonary hypertension, with reduced vascular remodelling and right ventricular hypertrophy. This 
phenotype was associated with reduced HIF-1α and PCNA, a marker of cell proliferation, levels in the 
lung, akin to chronically hypoxic HIF-1α +/- knockout mice45. Interestingly, a marked increase in RhoA 
expression was noted in the lungs of RhoB -/- mice. We did not seek to determine which cell types 
were responsible for the compensatory increase in RhoA expression. There is evidence this response is 
cell/tissue specific, as RhoA protein levels have been reported to be increased in macrophages
17
 but not 
in the hippocampus of RhoB-/- mice
46
. RhoA expression was not affected by manipulating RhoB in 
cultured vascular cells in this study or in published reports
29
. The data suggest that RhoB activity can be 
inhibited independently in vivo to reduce pulmonary artery pressure in pulmonary hypertension. 
 
The contribution of RhoB to vessel contractility in vivo remains to be established. Our preliminary data 
show no significant differences in contractile responses to high [K+], U46619 and phenylephrine or 
vasodilatory responses to sodium nitroprusside and acetylcholine in isolated intrapulmonary arteries 
from wild type and RhoB -/- mice (Supplementary Figure 11).  
 
RhoB is the only member of Rho GTPase family of proteins that is rapidly and transiently upregulated 
in response to stress conditions
12,47
 and our results show that increased RhoB activity has a protective 
effect on  pulmonary vascular cells under conditions of limited oxygen supply. Establishing upstream 
activators of RhoB will require further studies. RhoB expression and activity can be increased by 
numerous factors implicated in the pathogenesis of pulmonary hypertension, including tyrosine 
kinases
13, TGFβ/BMP/smad pathway26 and growth factors, FGF, EGF and PDGF22,28,48. TGF-β induces 
expression of RhoA and RhoB through smad2/3 signalling during fibroblast-myofibroblast 
differentiation
26
. RhoB expression can also be activated by BMP 4 protein of TGF-β family, known to 
be induced by hypoxia
49,50 
. Of relevance to pulmonary hypertension is a recent study that suggests a 
small non-coding microRNA, miR-21, may act as a negative regulator of RhoB expression. MiR-21 
levels are downregulated in human lung tissue and serum from patients with idiopathic PAH
51
. MiR-21 
inhibits endothelial cell migration and angiogenesis through repression of RhoB
52
 and regulates 
vascular smooth muscle cell proliferation and migration in hypoxia
53
.   
 
The activity of RhoB can be manipulated by prenylation inhibitors, opening avenues for new 
prospective treatment strategies. It is generally believed that farnesylated RhoB promotes cell growth 
and is pro-oncogenic, while geranylgeranylated RhoB has anti-oncogenic
54
 and pro-apoptotic effects
25
, 
although some reports show no differential effects
16
.  The anti-oncogenic effects of farnesyltransferase 
inhibitors are thought to result from an increase in the levels of geranylgeranylated RhoB
54
. In human 
pulmonary vascular cells, manumycin inhibited hypoxia-induced RhoB activation and prevented 
hypoxia-induced cell responses.  Considering the rapid turnover of RhoB protein in cells, most of the 
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effects of manumycin can be attributed to changes in RhoB activity. However, the pro-apoptotic effects 
of a more prolonged (>20 hr) treatment with manumycin may result from changes in farnesylation of 
other proteins important in the regulation of cell survival and metabolism such as Ras, Rheb, or nuclear 
lamins
55
. Farnesyltransferase inhibitors can increase the levels of geranylgeranylated RhoB in some cell 
types resulting in increased apoptosis
25
 or stress fibre formation
56
, but neither of these responses was 
observed in pulmonary vascular cells, suggesting that that most of the active RhoB in pulmonary 
vascular cells might be farnesylated. 
 
In conclusion, our work demonstrates the importance of RhoB as a mediator of hypoxia-induced 
pulmonary vascular remodelling and brings into focus its potential use as a drug target in pulmonary 
hypertension. As RhoB can compensate for the loss of function of RhoA, future research will need to 
establish whether targeting RhoB by farnesyltransferase inhibitors provide a therapeutic advance on 
less specific prenylation inhibitors, such as statins.   
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Figure 1. Hypoxia (1-24 hr) increases RhoB gene expression, protein expression and activity  
in HPASMCs (A) and HPAECs (B) and similarly RhoA (C, D). Representative examples of agarose 
gels with PCR products and Western blots are shown underneath the graphs; P≤0.05, **P≤0.01, 
comparisons with normoxic control, n=3. 
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Figure 2. Confocal images of HPAECs (A) and HPASMCs (B) cultured in normoxic or hypoxic (1 hr) 
conditions and stained for F-actin and VE-cadherin, showing increased stress fibre formation under 
hypoxic conditions. Activated RhoB (AdCARhoB) mimics the effects of hypoxia, while inhibitory 
mutant of RhoB (AdDNRhoB) or manumycin (5 µmol/L) added 1h before the hypoxic exposure, 
inhibit the effects of hypoxia. Bar=10µm. Accompanying changes in endothelial permeability were 
measured using the Transwell assay (C). *P≤0.05, **P≤0.01, comparisons with normoxic control; 
##P≤0.01, comparisons with hypoxic control, n=3.  
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Figure 3. Hypoxia and RhoB increase myosin light chain (MLC) phosphorylation of Ser19. Time 
course of MLC phosphorylation in HPAECs (A) and HPASMCs (B), with representative examples of 
Western blots shown underneath the graphs. Changes in the levels MLC P-Ser19 in HPASMCs over 
expressing GFP (Ad control); CARhoB, DNRhoB or DNRhoA alone or in combination with 
DNRhoB; or treated with manumycin (5 µmol/L), as indicated (C). Manumycin was added to the cells 
1 hr prior to hypoxic exposure and the cells were left in normoxia or in hypoxia for 2 hr. *P≤0.05, 
**P≤0.01, comparisons with normoxic control; #P≤0.05, ##P≤0.01, comparisons with hypoxic control 
n=4; (D) shows representative examples of Western blots corresponding to (C). In (B, C) n=4. 
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Figure 4. RhoB-induced morphological changes are inhibited by mDia1 siRNA or manumycin but not 
by Rho kinase inhibitor, Y-27632 (A). Western blot (B) of mDia1 protein expression in cells 
transfected with mDia1 siRNA. CARhoB over-expressing cells were transfected with mDia siRNA or 
were treated with manumycin (5 µmol/L, 2 hr) or Y-27632 (5 µmol/L, 6 hr) before cell fixation. F-actin 
is shown in the left panel, while the right panel shows cells over expressing GFP–V14RhoB. The arrow 
in the top left panel points to a contracting cell. Confocal microscopy; Bar=10 µm.   
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Figure 5. RhoB regulates hypoxia-induced growth responses in HPAECs (A) and HPASMCs (B). The 
cells over expressing Ad GFP (Ad control), AdCARhoB, AdDNRhoB, AdDNRhoA (alone or in 
combination with AdDNRhoB) were incubated in normoxia or in hypoxia for 48 hours, as indicated. 
Manumycin (5 µmol/L) was added at the start of hypoxic exposure. *P≤0.05, **P≤0.01, comparisons 
with normoxic control; #P≤0.05, ##P≤0.01, comparisons with hypoxic control, n=5  
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Figure 6. Effects of imatinib and RhoB on PDGF-stimulated (A, B) and hypoxia-induced (C, D) 
HPASMC proliferation and migration. MTS reduction was measured in cells expressing mutant Rho 
GTPases and incubated with PDGF-BB (20 µg/L) or exposed to hypoxia for 48 hr. Cell migration was 
studied 18 hr following treatment with PDGF or hypoxia. Manumycin (5 µmol/L) or imatinib (5 µmol 
/L) were added to the cells at the start of experiment. *P≤0.05, **P≤0.01, comparisons with 
normoxic/untreated control; #P≤0.05, ##P≤0.01, comparisons with hypoxic/PDGF-treated control, as 
appropriate. n=5  
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Figure 7. RhoB knockout attenuates development of chronic hypoxia-induced pulmonary hypertension. 
Right ventricular systolic pressure (RVSP) (A, B) and right ventricular hypertrophy (RVH) (C) were 
measured in wild type controls (C57BL/6) mice and RhoB -/- mice following 2 week exposure to 
normoxia or hypoxia. **P≤0.01, ***P≤0.001, comparison with normoxic controls; #P≤0.05, 
###P≤0.001, comparison with hypoxic controls; n=4-8. Representative RVSP polygraph tracings from 
the WT and RhoB-/- mice are shown (B). Percentage of muscularised vessels diameter ≤ 25 µm in lung 
sections (D) were reduced in RhoB-/- compared to wild type (WT) mice. *P≤0.05; ~500 vessels/lung 
section were scored in 4 WT and 4 RhoB-/- mice. Representative sections showing αSM actin staining 
in normoxic or the hypoxic wild type (WT) or RhoB-/- mice (E). The arrowheads in the middle panel 
point to the fully muscularised artery in hypoxic WT mice and partially muscularized artery in hypoxic 
RhoB -/- mice with magnified images shown in the right panel. Bar=10 µm. 
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Figure 8. RhoB is required for HIF stabilisation in vitro and in vivo. (A) HIF activity in U2OS-HRE-luc 
cells measured by luciferase reporter assay following 24 hr exposure to hypoxia. (B) HIF1-α protein 
expression in HPAECs; (C, D) HIF1-α and PCNA protein expression  in lungs from wild type (WT) and 
RhoB-/- mice, as indicated. (E) Inhibition of HIF1-α by DNRhoB but not DNRhoA in HPAECs by 
immunofluorescence and confocal microscopy; Bar=10 µm.  (F) Representative examples of HIF1-α 
and PCNA protein expression, Western blotting. Cells and animals were treated as indicated; 
manumycin was added at the start of hypoxic exposure. Grey bars show normoxic HIF-1α levels, while 
black bars show hypoxic HIF-1α levels. n=4 (A, B) and n=4-6 (C, D); *P≤0.05; **P≤0.01, compared 
with hypoxic controls (A, B) or compared with hypoxic WT controls (C, D).  
 
